spirogermanium has been researched along with methylformamide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abeloff, MD; Chang, YC; Ettinger, DS; Finkelstein, DM; Oken, MM; Ruckdeschel, JC; Smith, TJ | 1 |
| Blum, R; Chang, AY; Donehower, RC; Ettinger, DS; Finkelstein, DM; Green, M; Hahn, RG; Ruckdeschel, JC | 1 |
2 trial(s) available for spirogermanium and methylformamide
| Article | Year |
|---|---|
Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Small Cell; Drug Evaluation; Female; Formamides; Humans; Lung Neoplasms; Male; Middle Aged; Organometallic Compounds; Random Allocation; Spiro Compounds | 1990 |
Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): an Eastern Cooperative Oncology Group study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Female; Formamides; Germanium; Humans; Idarubicin; Lung Neoplasms; Male; Middle Aged; Organometallic Compounds; Prognosis; Random Allocation; Remission Induction; Spiro Compounds | 1989 |